Pia Gattinger, from MedUni Vienna's Centre for Pathophysiology, Infectiology and Immunology, was presented with the Life Science Research Award in the Applied Research category by the Austrian Society for Molecular Biosciences and Biotechnology (ÖGMBT). She received the award for her work on the development of a corona virus vaccine, which was developed in close cooperation with researchers at Karl Landsteiner University of Health Sciences.
The award for outstanding young scientists and their research achievements in the field of applied research was presented to Dr. Pia Gattinger for her publication on the development of a COVID-19 vaccine, which was developed at MedUni Vienna by her and her colleagues (led by Prof. Dr. Rudolf Valenta, who is also a visiting professor at Karl Landsteiner University of Health Sciences). This was developed in close cooperation with researchers from the Danube Allergy Research Cluster (Danube ARC) of Karl Landsteiner University of Health Sciences in Lower Austria.
The vaccine against the corona virus SARS-CoV-2 shows in preclinical data that it is effective against all known SARS-CoV-2 variants, including omicron, and is also effective in people who have not yet developed vaccine protection (non-responders). The protein-based vaccine targets the receptor binding domains (RBD) and unleashed a robust RBD-specific IgG antibody response in animal models and in human testing. The crucial immune protection that prevents docking and invasion of the body's cells occurs when the organism can produce antibodies specifically against the folded receptor binding domain (RBD) of the spike protein. The data of the study was published in the top journal Allergy, the European Journal of Allergy and Clinical Immunology.
Link to the publication: https://onlinelibrary.wiley.com/doi/10.1111/all.15305